PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF OBESITY COMPRISING LICARIN A OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS AN EFFECTIVE COMPONENT

摘要

The present invention relates to a pharmaceutical composition for preventing or treating obesity comprising licarin A (LA) or a pharmaceutically acceptable salt thereof as an effective component, and more specifically, to a pharmaceutical composition for preventing or treating obesity which can induce the differentiation of mesenchymal stem cells or white adipocytes to brown adipocytes or beige adipocytes by browning of adipocytes, wherein the browning indicates phenotypes including increased oxygen consumption, formation of multilocular lipid droplets, increased mitochondrial content and number of copies in cells, and increased expression amount of an uncoupling protein 1 (UCP1) gene. According to the present invention, the LA or a pharmaceutically acceptable salt thereof can effectively differentiate white adipocytes to brown or beige adipocytes through browning, and thus may be beneficially used as a drug or the like for treating metabolic disorders such as obesity, and may be extremely useful in the drug industry and the like.